Fresh analysis indicates that people who come off new weight-loss injections like semaglutide or tirzepatide may regain lost weight at a significantly accelerated pace than those who halt conventional lifestyle regimens.
Research printed in a leading medical journal shows that while obese individuals often shed substantial amounts of their total mass while undergoing treatment, the weight is regained at an estimated rate of nearly a kilo each month upon discontinuation.
"Individuals buying such treatments need to be informed of the potential of rapid rebound weight gain when the therapy ends," warns researcher Dr. Susan Jebb.
Such speed of recovery suggests a reversion to original weight in about a year and a half.
Analyzing Therapies
The research, which reviewed 37 of studies involving over 9,000 of patients, compared the effects of GLP-1 agonists with older methods.
The team note that people who shed pounds through diet and exercise typically see a more gradual weight regain—approximately 100 grams monthly—post-intervention.
Explaining the Rapid Regain
Doctors suggest the mechanism of the jabs is key to understanding the heightened weight return.
These medications imitate a body's own chemical called glucagon-like peptide-1, which controls feelings of fullness.
"Long-term administration of GLP-1 levels several times higher than the body's typical production could lead to the body to produce less of its own natural GLP-1, and could diminish sensitivity to its effects," noted Dr. Adam Collins, a nutrition specialist.
"Discontinuation of this hormone supplement means hunger is uncontrolled, making binge eating a significant risk."
An Ongoing Disease?
Health authorities suggest the injections for individuals with obesity-related medical conditions, accompanied by recommended diet and exercise modifications.
Professionals contend that, due to the high risk of weight regain, the treatment should be considered long-term.
This opinion is supported by pharmaceutical companies, who state that the findings "emphasize the chronic character of obesity," comparing it to managing diseases like high blood pressure.
Patient Experiences
Users who have discontinued the jabs explain a powerful return of hunger.
"I experienced something flipping and I was suddenly ravenous," described an individual.
This challenge is compounded if users have not adopted lasting dietary or behavioural modifications during therapy.
Significant Use
Figures suggest that millions of people in the UK have used weight-loss jabs in the last 12 months, with demand being substantial.
- Use is more common among women than men.
- The 40s and 50s age group shows the greatest level of interest.
- Many obtain the drugs through private healthcare rather than the NHS.
In conclusion, researchers caution that while GLP-1 drugs are powerful agents for shedding pounds, they are not a magic fix and long-term success hinges on ongoing behavioural support.
